Johnson & Johnson raises 2026 guidance on strong Q2 performance and new product launches, signaling confidence in growth.
Johnson & Johnson (JNJ) announced a 2026 sales midpoint target of $100.6 billion and an adjusted operational EPS range of $11.50 to $11.65. The update follows a strong second-quarter performance, with top- and bottom-line beats driving the revised outlook.
The company’s prior guidance was not disclosed, but the new range reflects optimism fueled by recent product launches and operational strength. Q2 2026 results exceeded expectations, reinforcing management’s confidence in sustained growth.
CEO Joaquin Duato highlighted the quarter’s success, emphasizing the role of new launches in supporting the raised targets. The guidance revision underscores JNJ’s positive trajectory amid broader market conditions.